Columvi (glofitamab)

Numéro de dossier de l’AMC: 22587
État des négociations:
Négociation conclue par une lettre d’intention
Indication(s):
Diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS), relapsed or refractory, DLBCL arising from follicular lymphoma (trFL), or primary mediastinal B-cell lymphoma (PMBCL), who have received two or more lines of systemic therapy and are ineligible to receive or cannot receive CAR-T cell therapy or have previously received CAR-T cell therapy, in adult patients
Promoteur/fabricant:
Hoffmann-La Roche Limited
Numéro de projet de l’AMC:
PC0320-000
Lettre-contrat de l’APP:
Conclusion du processus de négociation: